Candel Therapeutics (CADL) Net Cash Flow (2020 - 2023)
Historic Net Cash Flow for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$7.6 million.
- Candel Therapeutics' Net Cash Flow fell 624.56% to -$7.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$34.6 million, marking a year-over-year decrease of 17189.61%. This contributed to the annual value of $67.2 million for FY2024, which is 29408.57% up from last year.
- Per Candel Therapeutics' latest filing, its Net Cash Flow stood at -$7.6 million for Q4 2023, which was down 624.56% from -$8.9 million recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' Net Cash Flow registered a high of $64.1 million during Q3 2021, and its lowest value of -$10.8 million during Q1 2023.
- Its 4-year average for Net Cash Flow is $1.1 million, with a median of -$6.4 million in 2021.
- Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 296405.9% in 2021, then plummeted by 19237.09% in 2023.
- Candel Therapeutics' Net Cash Flow (Quarter) stood at $16.8 million in 2020, then tumbled by 134.19% to -$5.7 million in 2021, then dropped by 24.09% to -$7.1 million in 2022, then dropped by 6.25% to -$7.6 million in 2023.
- Its last three reported values are -$7.6 million in Q4 2023, -$8.9 million for Q3 2023, and -$7.4 million during Q2 2023.